secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001847903-22-000082
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa Q3 net loss $53.9M, cash $444.8M; SerpinPC and LB101 on track
----------------------------------------------------------------------

- Net loss $53.9M in Q3 2022 vs $40.2M in Q3 2021; R&D spend $36.7M vs $25.9M.
- Cash $444.8M provides runway into 2026; no additional draw on Oberland facility.
- SerpinPC pivotal program: PRESent-5 observational study starting Q4 2022; Phase 2a OLE data at ASH Dec 10.
- LB101 IND submission for PD-L1xCD47 bispecific on track for late 2022.
- SerpinPC granted FDA Orphan Drug Designation in September 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790322000082/0001847903-22-000082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790322000082/cnta-20221110.htm
  HTML page:      https://secwatch.observer/filing/0001847903-22-000082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer